Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) issued its earnings results on Wednesday. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.01), MarketWatch Earnings reports. Amneal Pharmaceuticals had a return on equity of 61.08% and a net margin of 0.68%. The company had revenue of $497.30 million during the quarter, compared to analyst estimates of $502.29 million. During the same period in the prior year, the business earned $0.19 earnings per share. Amneal Pharmaceuticals’s quarterly revenue was up .9% on a year-over-year basis. Amneal Pharmaceuticals updated its FY22 guidance to $0.80-0.85 EPS.
Shares of NYSE AMRX traded down $0.11 during midday trading on Friday, reaching $3.44. 8,875 shares of the company traded hands, compared to its average volume of 701,808. The company has a market cap of $1.04 billion, a price-to-earnings ratio of 39.44, a PEG ratio of 0.22 and a beta of 1.24. The stock has a 50-day moving average price of $4.10 and a 200 day moving average price of $4.52. Amneal Pharmaceuticals has a 52 week low of $3.26 and a 52 week high of $6.21. The company has a debt-to-equity ratio of 7.11, a current ratio of 2.35 and a quick ratio of 1.57.
Several analysts recently weighed in on AMRX shares. Barclays cut their price objective on shares of Amneal Pharmaceuticals from $8.00 to $7.00 in a research report on Thursday, April 28th. Zacks Investment Research upgraded Amneal Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday.
Amneal Pharmaceuticals Company Profile (Get Rating)
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
- Get a free copy of the StockNews.com research report on Amneal Pharmaceuticals (AMRX)
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
- Kellogg Company Flexes Pricing Power, Shares Move Higher
- Peak Growth Is Over For Etsy
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.